Madrigal Pharmaceuticals

Madrigal reported Q2 2026 Rezdiffra revenue of $364 million and more than 50,000 patients in treatment, sees the MASH market as still in an early stage with only about a 10% diagnosis and penetration rate, and expects continued double‑digit growth. Management warns of near‑term pressure on gross‑to‑net margins for 2026, but expects relief in 2027 and is seeking Medicare contracts for 2027. At the same time, Madrigal is building a capital‑efficient pipeline with an oral GLP‑1 (Orforglipron), the DGAT2 inhibitor Ervogastat and a PNPLA3‑siRNA; key catalysts include Phase‑II combination studies and the Phase‑III MAESTRO study in F4 cirrhosis. » More on de.investing.com

Madrigal reported Q2 2026 revenue of $364 million (+71% y/y) and trailing twelve‑month revenue of about $1.3 billion; the number of active Rezdiffra patients is over 50,000. The company is building a pipeline of ten active compounds that were prepaid for less than $300 million and plans three combination studies with Resmetirom for 2027. Management views Rezdiffra as a backbone therapy with potential for indication expansions up to cirrhotic stages; patent protection runs through 2045. European revenues are likely to be constrained in 2026 due to price controls. » More on de.investing.com

Shareholders of Madrigal Pharmaceuticals voted in favor of the 2026 Stock Plan and the 2026 Employee Stock Purchase Plan, as well as a non-qualified deferred compensation plan for executive officers and outside directors that becomes effective August 1, 2026. Dr. Rebecca Taub will move to an advisory role on July 1, 2026, remains a class II director, and Julian C. Baker, Daniel J. Brennan and James M. Daly were reclassified/confirmed as class I directors. The company retained PricewaterhouseCoopers as auditor and received, on a non-binding basis, shareholder approval of executive compensation. Madrigal reported better-than-expected Q1 2026 results (EPS -$3.25; revenue $311.3 million) and saw mixed analyst reactions to Rezdiffra with price targets ranging from $542 to $737; the stock trades at $499.86 and is estimated to remain below fair value. » More on de.investing.com